CD Skripsi
Kepentingan India Menolak Permohonan Hak Paten Obat Kanker Dari Perusahaan Novartis Negara Swiss
This study is an international political economy study explaining about India's interest in applying protection policy to its pharmaceutical industry. India's protective form is to include article 3 (d) in the 2005 amendment as a reference. This study is interesting because it describes the generics and patents. India is the third largest country in the production of generic drugs. India can do that after they make some revolutions in Indian intellectual property law.
This research uses explanatory research methods, and collects data from several sources such as books, journals, official publications and relevant websites. This research uses the perspective of mercantilism, in this perspective the State becomes the main actor who actively and rationally organizes the economy in order to increase the power and power of the State. The level of analysis used in this study is the nation state. This study also uses the theory of protectionism which is the state's efforts to protect the interests of the country, focusing on the economy internationally.
The results of this study indicate that India rejected the application of Patent for cancer drugs proposed by Novartis will disrupt India's pharmaceutical industry is able to grow very rapidly to become the largest producer of generic drugs in the world. And filing a patent for cancer drug (Glivec) by a Novartis that worries India. Therefore, India tries to protect its pharmaceutical industry under article 3 (d) of the 2005 amendment law.
Keywords: Patent rights, Pharmaceutical industry, India, Protection, Generic drugs
Tidak tersedia versi lain